Home › Research › How common it is
Type 2 diabetes and late-onset Alzheimer’s disease and related dementia: A longitudinal cohort study integrating polygenic risk score
Sohyun Jeong, Lisha Lin, Álvaro Pascual‐Leone, Yi‐Hsiang Hsu. Journal of Alzheimer s Disease, 2025-03-25
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background The inherent genetic effects were not established between type 2 diabetes (T2DM) and Alzheimer's disease and related dementia (ADRD). Objective We aimed to investigate the association between T2DM and ADRD by integrating T2DM polygenic risk score (PRS) and applying matching in every subgroup. Methods We utilized UK Biobank First-occurrences datasets. T2DM were 1:1 matched to non-T2DM using propensity scores generated by 8 covariates; age at diagnosis, sex, cerebrovascular disease, ischemic heart disease, hypertensive disorders, lipid disorders, obesity, and mood disorders. T2DM PRS was additionally matched in T2DM PRS matched analysis. Subgroup analyses by age at diagnosis, sex, and APOE4 genotype were performed with the same matching criteria within each subgroup. Cox proportional hazard and Fine & Gray competing risk model were utilized. Results In T2DM PRS unmatched cohort, 24,583 T2DM were 1:1 matched to non-T2DM. The mean age at diagnosis was around 62 years old, with females constituting around 40%. Up to 25-year follow-up, ADRD rate/1000 person-years was 0.88 versus 1.52 (Non-T2DM versus T2DM); PRS unmatched (cHR: 1.72, 95% CI: 1.46–2.03) and matched (cHR:1.75, 95% CI: 1.47–2.09). Except for older age onset (≥75 years), the other subgroups demonstrated significantly increased ADRD risks in T2DM. T2DM PRS was higher in non-ADRD group across all subgroups. Contrarily, T2DM PRS was higher in ADRD in younger onset group (<55 years). Conclusions T2DM is one of the strong risk factors of ADRD but genetic T2DM effect does not contribute to ADRD risk. However, a genetic link might be present in younger age onset group.
What this study adds
Evidence grade: Moderate
In a UK Biobank analysis, people with type 2 diabetes had a higher risk of Alzheimer's disease and related dementia than those without, across most subgroups. Reported effect size: HR: 1.72; HR:1.75.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Jeong, S., Lin, L., Pascual‐Leone, Á., & Hsu, Y. (2025). Type 2 diabetes and late-onset Alzheimer’s disease and related dementia: A longitudinal cohort study integrating polygenic risk score. Journal of Alzheimer s Disease. https://doi.org/10.1177/13872877251326107
Vancouver
Jeong S, Lin L, Pascual‐Leone Á, Hsu Y. Type 2 diabetes and late-onset Alzheimer’s disease and related dementia: A longitudinal cohort study integrating polygenic risk score. Journal of Alzheimer s Disease. 2025. doi:10.1177/13872877251326107. PMID: 40129417.
BibTeX
@article{jeong2025-40129417,
author = {Jeong, Sohyun and Lin, Lisha and Pascual‐Leone, Álvaro and Hsu, Yi‐Hsiang},
title = {{Type 2 diabetes and late-onset Alzheimer’s disease and related dementia: A longitudinal cohort study integrating polygenic risk score}},
journal = {Journal of Alzheimer s Disease},
year = {2025},
doi = {10.1177/13872877251326107},
pmid = {40129417},
url = {https://doi.org/10.1177/13872877251326107}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Results In T2DM PRS unmatched cohort, 24,583 T2DM were 1:1 matched to non-T2DM.
- Up to 25-year follow-up, ADRD rate/1000 person-years was 0.88 versus 1.52 (Non-T2DM versus T2DM); PRS unmatched (cHR: 1.72, 95% CI: 1.46–2.03) and matched (cHR:1.75, 95% CI: 1.47–2.09).
- Except for older age onset (≥75 years), the other subgroups demonstrated significantly increased ADRD risks in T2DM.
Why it matters
In a UK Biobank analysis, people with type 2 diabetes had a higher risk of Alzheimer's disease and related dementia than those without, across most subgroups. This links type 2 diabetes to dementia risk but does not show that treating diabetes prevents dementia.
New to this subject? Start with our plain-English guide: Alzheimer's in numbers →
Study details
- Effect sizeHR: 1.72; HR:1.75
- Evidence strengthModerate
How this study scored 46/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Alzheimer s Disease) |
| Journal's citation record | 2 / 4 | Journal of Alzheimer s Disease: journal h-index 218 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 10 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 6.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 1 / 4 | Cited 10 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Yi‐Hsiang Hsu: h-index 14 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40129417) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 46 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 19.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in How common it is from nearby years
Also tagged “biobank”
1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.